The stock of C4 Therapeutics Inc (CCCC) has seen a -6.17% decrease in the past week, with a 8.65% gain in the past month, and a 0.70% flourish in the past quarter. The volatility ratio for the week is 8.60%, and the volatility levels for the past 30 days are at 9.80% for CCCC. The simple moving average for the last 20 days is -5.76% for CCCC stock, with a simple moving average of -56.57% for the last 200 days.
Is It Worth Investing in C4 Therapeutics Inc (NASDAQ: CCCC) Right Now?
The 36-month beta value for CCCC is also noteworthy at 2.94. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for CCCC is 54.24M, and at present, short sellers hold a 11.75% of that float. The average trading volume of CCCC on July 02, 2025 was 1.22M shares.
CCCC) stock’s latest price update
The stock price of C4 Therapeutics Inc (NASDAQ: CCCC) has plunged by -4.30% when compared to previous closing price of $1.51, but the company has seen a -6.17% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-16 that CCCC’s valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC’s cash runway into 2027, reducing dilution risk and supporting ongoing development and partnerships.
Analysts’ Opinion of CCCC
Many brokerage firms have already submitted their reports for CCCC stocks, with Wells Fargo repeating the rating for CCCC by listing it as a “Overweight.” The predicted price for CCCC in the upcoming period, according to Wells Fargo is $12 based on the research report published on December 19, 2024 of the previous year 2024.
Stephens, on the other hand, stated in their research note that they expect to see CCCC reach a price target of $4. The rating they have provided for CCCC stocks is “Equal-Weight” according to the report published on November 18th, 2024.
JP Morgan gave a rating of “Neutral” to CCCC, setting the target price at $6 in the report published on January 29th of the previous year.
CCCC Trading at -3.69% from the 50-Day Moving Average
After a stumble in the market that brought CCCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.14% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CCCC starting from Boyle Scott N, who sale 669 shares at the price of $3.15 back on Feb 18 ’25. After this action, Boyle Scott N now owns 107,805 shares of C4 Therapeutics Inc, valued at $2,107 using the latest closing price.
Boyle Scott N, the Chief Business Officer of C4 Therapeutics Inc, sale 490 shares at $3.15 during a trade that took place back on Feb 14 ’25, which means that Boyle Scott N is holding 110,842 shares at $1,544 based on the most recent closing price.
Stock Fundamentals for CCCC
Current profitability levels for the company are sitting at:
- -2.93 for the present operating margin
- 0.85 for the gross margin
The net margin for C4 Therapeutics Inc stands at -2.6. The total capital return value is set at -0.42. Equity return is now at value -45.55, with -28.77 for asset returns.
Based on C4 Therapeutics Inc (CCCC), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -1.25.
Currently, EBITDA for the company is -103.37 million with net debt to EBITDA at -0.13. When we switch over and look at the enterprise to sales, we see a ratio of 3.0. The receivables turnover for the company is 4.96for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.70.
Conclusion
In summary, C4 Therapeutics Inc (CCCC) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
